RxDoctor Payments DataLook up a doctor →

Tami Bruce, MD

Internal Medicine · Mesa, AZNPI 1548324254

Payments from drug & device makers

$975,548in general payments, 2019–2025

Across 1,042 payments — averaging $936.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$591K
  • Eli Lilly$109K
  • Sanofi US Services Inc.$105K
  • Akcea Therapeutics, Inc.$69K
  • AbbVie$45K
  • AstraZeneca$25K
  • plus $32K from 54 others
$6,309in research payments, 2019–2025

Across 2 payments — averaging $3154.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$6K

What the payments were for

  • Travel & lodging$2,18018%
  • Food & beverage$10,14882%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck104$590,504
Eli Lilly13$109,082
Sanofi US Services Inc.107$104,677
Akcea Therapeutics, Inc.234$69,279
AbbVie(2 entities)91$45,091
AstraZeneca12$24,532
Kowa Research Institute, Inc.23$15,608
Astrazeneca UK Limited2$6,129
Rhythm Pharmaceuticals, Inc.1$2,648
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC47$731
Gilead30$662
Boehringer Ingelheim37$654
GSK36$653
Johnson & Johnson(2 entities)39$565
Lilly USA, LLC26$397
Regeneron Healthcare Solutions, Inc.19$392
United Therapeutics Corporation16$333
Amgen18$276
Ardelyx, Inc.14$269
Sanofi10$261
Mylan Specialty L.p.11$195
Baxter Healthcare9$163
Grifols USA, LLC8$149
Abbott8$147
Novo Nordisk10$147
Bristol Myers Squibb11$145
Daiichi Sankyo Inc.7$121
Ironwood Pharmaceuticals, Inc8$116
Advanced Respiratory, Inc7$107
Novartis5$97
Actelion Pharmaceuticals US, Inc.4$89
Boston Scientific4$69
Nestle Healthcare Nutrition Inc.4$67
Viatris Specialty LLC4$66
Pulmonx Corporation3$64
Takeda Pharmaceuticals U.S.A., Inc.3$60
Dexcom, Inc.2$55
QOL Medical, LLC3$55
Pfizer4$52
Electromed, Inc.4$50
Covis Pharma GmbH2$48
Sanofi Pasteur Inc.3$47
Celltrion USA Inc.2$46
Redhill Biopharma Inc.3$45
Intercept Pharmaceuticals, Inc.3$44
Topcon Healthcare Solutions, Inc.1$39
Sunovion Pharmaceuticals Inc.3$39
Ferring Pharmaceuticals Inc.2$34
Aimmune Therapeutics, Inc.1$31
Hologic Sales And Service, LLC2$31
Fresenius Kabi USA, LLC1$31
Impulse Dynamics (USA) Inc.2$30
Mallinckrodt Hospital Products Inc.1$29
Phathom Pharmaceuticals, Inc.1$26
Xeris Pharmaceuticals, Inc.1$25
Mylan Institutional Inc.1$24
Verona Pharma, Inc.1$23
Biocon Biologics Inc1$22
Phadia US Inc.1$19
Inspire Medical Systems, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$975,548 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$169,309
Medicare patients
440
Services billed
2,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin65$90,292
Synjardy XrEmpagliflozin/Metformin Hcl40$67,898
OzempicSemaglutide59$61,356
TrulicityDulaglutide38$59,513
RybelsusSemaglutide27$48,179
EliquisApixaban33$40,099
XareltoRivaroxaban20$33,753
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$26,518
MounjaroTirzepatide19$22,167
Tresiba Flextouch U-200Insulin Degludec16$19,785
Breo ElliptaFluticasone/Vilanterol21$13,517
LinzessLinaclotide13$11,340
Rosuvastatin Calcium462$6,244
Levothyroxine Sodium531$5,392
Atorvastatin Calcium431$4,955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$654$158,190105 claims
Novo NordiskOzempic, Rybelsus$147$109,53686 claims
Lilly USA, LLCTrulicity, Mounjaro$397$81,68057 claims
PfizerEliquis$52$40,09933 claims
GSKAnoro Ellipta, Breo Ellipta$653$40,03542 claims
Johnson & JohnsonXarelto$565$33,75320 claims
AbbVieLinzess, Synthroid$45,091$15,11467 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →